American Water Works Company (AWK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 May, 2026Voting matters and shareholder proposals
Proposal 3 concerns the ratification of PwC as the independent auditor for the upcoming year, with the company emphasizing PwC's service quality, institutional knowledge, and experience with regulated utilities.
The company addressed shareholder inquiries regarding auditor selection, highlighting the limited pool of eligible audit firms due to independence requirements.
Audit committee and external auditor matters
PwC has served as independent auditor for an extended period, with lead audit partner rotations every five years to maintain independence.
The most recent lead audit partner rotation occurred in Q1 2023.
The audit committee values PwC's independence, objectivity, and professional skepticism, as well as strong communication with management and the committee.
Latest events from American Water Works Company
- Q1 2026 EPS was $1.01, revenue rose 5.7%, dividend up 8.2%, and merger progress continues.AWK
Q1 20261 May 2026 - Annual meeting to vote on directors, compensation, auditor, equity plans, and officer exculpation.AWK
Proxy filing22 Apr 2026 - 2025 EPS up 8.9%, $3.2B invested, merger approved, 2026 guidance and growth targets affirmed.AWK
Q4 202512 Apr 2026 - Shareholders approved the merger share issuance, paving the way for a major utility combination.AWK
EGM 202611 Apr 2026 - Annual meeting covers director elections, auditor ratification, and key governance proposals.AWK
Proxy filing24 Mar 2026 - Shareholders to vote on key governance, compensation, and merger-related proposals at the 2026 meeting.AWK
Proxy Filing13 Mar 2026 - 2026 EPS guidance affirmed with strong growth, major investments, and a pending merger.AWK
Investor presentation10 Mar 2026 - 2024 EPS guidance raised to $5.25–$5.30, with strong investment and growth targets affirmed.AWK
Q2 20242 Feb 2026 - Q3 EPS up to $1.80, 2024/2025 guidance affirmed, $230M acquisition and strong growth plans.AWK
Q3 202417 Jan 2026